SCHEMBL6465607

SCHEMBL6465607

COc1ccc(OC)c2c(C)nc(Nc3nc(OC(=O)C(F)(F)F)c4cc(C)cc(C)c4n3)nc12

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.35
TP53 P04637 1/20 0.35
STAT1 P42224 1/20 0.35
MAPT P10636 7/20 0.34
KDM4E B2RXH2 5/20 0.34
POLB P06746 3/20 0.34
GAA P10253 3/20 0.33
MAPK1 P28482 2/20 0.33
NPC1 O15118 1/20 0.33
SYK P43405 1/20 0.33
ALDH1A1 P00352 4/20 0.32
PKM P14618 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
HSD17B10 Q99714 2/20 0.31
LMNA P02545 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6470122 0.95 STAT3 (0.35) STAT3TP53STAT1MAPTKDM4E
SCHEMBL6470120 0.87 STAT3 (0.36) STAT3TP53STAT1MAPTKDM4E
SCHEMBL6466279 0.85 MAPT (0.33) STAT3TP53STAT1MAPTKDM4E
SCHEMBL6469547 0.85 MAPT (0.38) STAT3TP53STAT1MAPTKDM4E
SCHEMBL6467957 0.84 STAT3 (0.39) STAT3TP53STAT1MAPTKDM4E
Trifluoroacetic Acid SCHEMBL6465606 0.84 STAT3 (0.36) STAT3TP53STAT1MAPTKDM4E
SCHEMBL6469411 0.84 KMT2A (0.41) TP53MAPTPOLBGAAMAPK1
SCHEMBL6467985 0.84 POLB (0.41) KDM4EPOLBGAAALDH1A1HSD17B10
SCHEMBL6469269 0.83 POLB (0.37) KDM4EPOLBGAA
SCHEMBL6467851 0.83 MAPT (0.36) STAT3TP53STAT1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB STAT3 3341/4885TP53 1339/4885STAT1 1527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.